Ligand, Janssen Enter R&D Deal

Date : 07/11/2018 @ 5:48PM
Source : Dow Jones News
Stock : Ligand Pharmaceuticals Incorporated (LGND)
Quote : 147.8  0.0 (0.00%) @ 4:00AM

Ligand, Janssen Enter R&D Deal

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Historical Stock Chart

6 Months : From May 2018 to Nov 2018

Click Here for more Ligand Pharmaceuticals Incorporated Charts.
   Micah Maidenberg 

Subsidiaries of Ligand Pharmaceutical Inc. (LGND) and Johnson & Johnson (JNJ) have entered into a research-and-development agreement focused on a "transgenic chicken platform" aimed at generating and discovering antibodies for humans, according to a securities filing.

Ligand's company Crystal Bioscience Inc., and Janssen Research & Development LLC, which is part of the Janssen Pharmaceutical Cos. of Johnson & Johnson, agreed to work together on Ligand's development of the platform, the filing said.

Under the deal, Ligand will be able to earn milestone payments contingent on various deliverables and will be able to sell the platform to others in the market.


Write to Micah Maidenberg at


(END) Dow Jones Newswires

July 11, 2018 17:33 ET (21:33 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

Latest LGND Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.